New Mexico Governor Michelle Lujan Grisham (D) signed SB 219, the Medical Psilocybin Act, which will establish the third state-legal psilocybin access system in the US.
the Act creates a framework through which patients with qualifying conditions can access and use non-synthetic psilocybin through consultation with a licensed healthcare provider.
Qualifying conditions, according to the bill, are ‘major treatment-resistant depression’, PTSD, substance use disorders and end-of-life care, as well as other conditions that the department might approve.
The program, which is set to be ready for launch by December 31st, 2027, now enters a development period where the state’s Department of Health—which is tasked with overseeing the system—will work with a nine-person Medical Psilocybin Advisory Board to formulate rules.
That advisory board must, according to the language of the Act, include at least one member from an Indigenous group, one mental health equity advocate, one representative from the health care authority, and one veteran. That will include the qualifications and standards required of trainers, facilitators, cultivators, and so on; as well as treatment protocols, dosage standards, approved settings, data collection requirements, and so on.
Some of these elements are baked into the Act. For example, the treatment protocol will entail a minimum of one preparation session and one post-administration integration setting, all of which must happen at approved sites. However, there is plenty to flesh out.
Read more about the legislation at
BREAKING: New Mexico Passes Nation’s First Legislature-Driven Psilocybin Access Act
